2024
COVID-19 in pregnancy: Perinatal outcomes and complications
Akinosoglou K, Schinas G, Papageorgiou E, Karampitsakos T, Dimakopoulou V, Polyzou E, Tzouvelekis A, Marangos M, Papageorgiou D, Spernovasilis N, Adonakis G. COVID-19 in pregnancy: Perinatal outcomes and complications. World Journal Of Virology 2024, 13 DOI: 10.5501/wjv.v13.i4.96573.Peer-Reviewed Original ResearchNeonatal intensive care unitIntensive care unitPregnant womenPerinatal outcomesGestational agePredictor of adverse fetal outcomesPregnant COVID-19 patientsOutcomes of pregnant womenCare unitAdverse fetal outcomesED presentationsPreterm delivery rateUnfavorable perinatal outcomesEmergency departmentRisk of severe coronavirus disease 2019Severe coronavirus disease 2019Invasive mechanical ventilationDelayed ED presentationsPredictors of hospitalizationFetal outcomesPreterm deliveryPerinatal morbidityCOVID-19 patientsClinical characteristicsTreatment modalitiesThe Clinical Utility of Pulmonary Function Tests in the Diagnosis and Characterization of Central Airway Obstruction: A Narrative Review
Ampazis D, Vlachakos V, Anagnostopoulos N, Tzouvelekis A, Sampsonas F. The Clinical Utility of Pulmonary Function Tests in the Diagnosis and Characterization of Central Airway Obstruction: A Narrative Review. Journal Of Clinical Medicine 2024, 13: 6299. DOI: 10.3390/jcm13216299.Peer-Reviewed Original ResearchCorrigendum to “Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease” [Autoimmunity Reviews - Volume 23, Issue 6, June 2024, 103582]
Guiot J, Miedema J, Cordeiro A, De Vries-Bouwstra J, Dimitroulas T, Søndergaard K, Tzouvelekis A, Smith V. Corrigendum to “Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease” [Autoimmunity Reviews - Volume 23, Issue 6, June 2024, 103582]. Autoimmunity Reviews 2024, 23: 103641. PMID: 39369613, DOI: 10.1016/j.autrev.2024.103641.Peer-Reviewed Original ResearchInterstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations
Sampsonas F, Bosgana P, Bravou V, Tzouvelekis A, Dimitrakopoulos F, Kokkotou E. Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations. Genes 2024, 15: 934. PMID: 39062713, PMCID: PMC11276289, DOI: 10.3390/genes15070934.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseLung cancerLung diseaseDriver mutationsImproved survivalTreatment optionsChronic inflammationPathogenetic pathwaysNon-small cell lung cancerConcurrent interstitial lung diseaseCell lung cancerSites of chronic inflammationAnti-fibrotic medicationsCurrent treatment optionsIdiopathic pulmonary fibrosisDiseases associated with chronic inflammationIncidence of lung cancerPersonalized medicine approachPrompt diagnosisClinical entityNon-smallPulmonary fibrosisNSCLCSurvival ratePatientsPractical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease
Guiot J, Miedema J, Cordeiro A, De Vries-Bouwstra J, Dimitroulas T, Søndergaard K, Tzouvelekis A, Smith V. Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease. Autoimmunity Reviews 2024, 23: 103582. PMID: 39074630, DOI: 10.1016/j.autrev.2024.103582.Peer-Reviewed Original ResearchInterstitial lung diseaseConnective tissue diseaseConnective tissue disease-related interstitial lung diseaseLung diseaseTissue diseaseCTD-ILDJourney of patientsProgression of interstitial lung diseaseManagement of CTD-ILDComplication of connective tissue diseasesFollow-up of patientsIdentification of interstitial lung diseaseHeterogeneous group of diseasesDisease activity of patientsActivity of patientsPulmonary function testsInternational expert panelGroup of diseasesMultidisciplinary teamExpert panelProgressive diseaseChest radiographyDisease activityClinical examinationFollow-upEBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature
Sampsonas F, Komninos D, Sotiropoulou V, Katsaras M, Gkanetsou D, Papaioannou O, Tsiri P, Tzelepi V, Tzouvelekis A. EBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature. Pneumon 2024, 37: 1-4. DOI: 10.18332/pne/188870.Peer-Reviewed Original ResearchPresenting clinical and imaging features of patients with clinically amyopathic interstitial lung disease associated with myositis-specific autoantibodies
Tzilas V, Tzouvelekis A, Sotiropoulou V, Panopoulos S, Bouros E, Avdoula E, Ryu J, Bouros D. Presenting clinical and imaging features of patients with clinically amyopathic interstitial lung disease associated with myositis-specific autoantibodies. Frontiers In Medicine 2024, 11: 1392659. PMID: 38711778, PMCID: PMC11070581, DOI: 10.3389/fmed.2024.1392659.Peer-Reviewed Original ResearchMyositis-specific autoantibodiesPresence of myositis-specific autoantibodiesImaging features of patientsChest imaging studiesIdiopathic inflammatory myopathiesFeatures of patientsInterstitial lung diseaseIncreased CK levelsSignificant diagnostic challengeMedian DLCOMedian FVCHRCT patternGottron's papulesUIP patternMedian agePresenting symptomsLung involvementInflammatory myopathiesRadiological featuresDiagnostic challengeMuscle involvementInspiratory cracklesRaynaud's phenomenonComputer-assisted searchLung diseaseModified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis
Kreuter M, Lee J, Tzouvelekis A, Oldham J, Molyneaux P, Weycker D, Atwood M, Samara K, Kirchgässler K, Maher T. Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis. ERJ Open Research 2024, 10: 00666-2023. PMID: 39076530, PMCID: PMC11284599, DOI: 10.1183/23120541.00666-2023.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisWhite blood cellsRed blood cellsNeutrophil countMonocyte countPulmonary fibrosisHemoglobin levelsRandomised phase III trialBaseline white blood cellC-statisticIPF outcomesBlood cellsTrials of pirfenidoneIdiopathic pulmonary fibrosis progressionImprove prediction of outcomeRed blood cell variablesBlood cell countPredictive of outcomeStudy outcomesRed blood cell parametersMortality prediction toolRespiratory-related hospitalisationEosinophil countRetrospective analysisMultivariate analysisBridges of Pulmonology 2023 proceedings: Highlights in the field of interstitial lung diseases
Sotiropoulou V, Tsiri P, Gogali A, Tzilas V, Bouros D, Tzouvelekis A. Bridges of Pulmonology 2023 proceedings: Highlights in the field of interstitial lung diseases. Pneumon 2024, 37: 1-4. DOI: 10.18332/pne/183960.Peer-Reviewed Original ResearchMycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis
Lombardi F, Stewart I, Fabbri L, Adams W, Kawano-Dourado L, Ryerson C, Jenkins G, Consortium R, Cavalcanti A, Mojibian A, Bravery A, Goodwin A, Etges A, Boshoff A, Guenther A, Briggs A, Palmer A, Wilson A, Crawshaw A, Anna-MariaHoffmann-Vold A, Holland A, Gordon A, Prasse A, Tzouvelekis A, Trachalaki A, Wells A, Nair A, Wendelberger B, Hope-Gill B, Gooptu B, Baldi B, Crestani B, Polanczyk C, Vancheri C, Robalo C, Summers C, Grainge C, Ryerson C, von Garnier C, Huntley C, Ravaglia C, Valenzuela C, Hayton C, McCarthy C, Chambers D, Wang D, Bablis D, Thicket D, Turner D, Talwar D, Adegunsoye D, Anand D, Dhasmana D, Parek D, Griffiths D, Richards D, Santucci E, Bendstrup E, Balestro E, Tsitoura E, Falaschetti E, Karlsen E, Gupta E, Farrand E, Khan F, Chua F, Martinez F, Bonella F, Lombardi F, Hunninghake G, Saini G, Chalmers G, Jenkins G, Gudmundsson G, Collard H, Parfrey H, Prosch H, Fainberg H, Adamali H, Stewart I, Forrest I, Glaspole I, Bauer-Ventura I, Noth I, Cox I, Strambu I, Sellares J, Eaden J, Johnston J, Swigris J, Blaikley J, Kim J, Chung J, Lasky J, Jacob J, Lee J, Behr J, Storrer K, Negrelli K, Lewandowska K, Johnson K, Antoniou K, Hostettler K, Johannson K, Hurley K, Hett K, Schwarzkopf L, Fabbri L, Price L, Pearmain L, Kawano-Dourado L, Galvin L, Spencer L, Watson L, Crowley L, Richeldi L, Piccari L, Chambour M, Molina-Molina M, Jones M, Spears M, Toshner M, Wijsenbeek-Lourens M, Brutsche M, Vasakova M, Quintana M, Gibbons M, Henry M, Keane M, Kreuter M, Hatieganu M, Sadatsafavi M, Kaminski N, Chaudhuri N, Weatherley N, Hirani N, Babes O, Spagnolo P, Beirne P, Bryce P, George P, Molyneaux P, Ortega P, Crisan-Dabija R, Maida R, Borie R, Lewis R, Rolo R, Guler S, Paganoni S, Singh S, Freitas S, Piciucchi S, Malik S, Barratt S, Hart S, Dal Corso S, Fletcher S, Stanel S, Bianchi S, Jones S, Adams W. Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis. BMJ Open Respiratory Research 2024, 11: e002163. PMID: 38413120, PMCID: PMC10973691, DOI: 10.1136/bmjresp-2023-002163.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseMycophenolate mofetilRandomised controlled trialsPrimary endpointLung diseasePulmonary functionEfficacy of mycophenolate mofetilPreservation of pulmonary functionInterstitial lung disease diagnosisMMF efficacyPrimary endpoint analysisProspective observational studySystematic reviewNo language restrictionsGrading of RecommendationsAzathioprine efficacyConcomitant steroidsAzathioprine treatmentImmunomodulatory treatmentRandomised controlled trial designSecondary endpointsPlacebo comparatorRetrospective studyAzathioprineSubgroup analysisA case report of late pleural effusion and hemoptysis as a result of pulmonary vein stenosis due to atrial fibrillation ablation
Komninos D, Sotiropoulou V, Katsaras M, Tzouvelekis A. A case report of late pleural effusion and hemoptysis as a result of pulmonary vein stenosis due to atrial fibrillation ablation. Pneumon 2024, 37: 1-4. DOI: 10.18332/pne/178471.Peer-Reviewed Original Research
2023
Bronchoscopy-related outbreaks and pseudo-outbreaks: A systematic review
Kakoullis L, Economidou S, Mehrotra P, Panos G, Karampitsakos T, Stratakos G, Tzouvelekis A, Sampsonas F. Bronchoscopy-related outbreaks and pseudo-outbreaks: A systematic review. Infection Control And Hospital Epidemiology 2023, 45: 509-519. PMID: 38099453, DOI: 10.1017/ice.2023.250.Peer-Reviewed Original ResearchCoexistence of Autoimmune Pulmonary Alveolar Proteinosis With Small Cell Lung Cancer in a Man Presenting With Acute Onset Respiratory Failure
Papaioannou O, Koulousousa E, Karampitsakos T, Tzouvelekis A. Coexistence of Autoimmune Pulmonary Alveolar Proteinosis With Small Cell Lung Cancer in a Man Presenting With Acute Onset Respiratory Failure. Cureus 2023, 15: e48330. PMID: 38060701, PMCID: PMC10698294, DOI: 10.7759/cureus.48330.Peer-Reviewed Original ResearchSmall cell lung cancerAutoimmune pulmonary alveolar proteinosisCell lung cancerPulmonary alveolar proteinosisAlveolar proteinosisLung cancerAcute onset respiratory failureMacrophage colony-stimulating factor antibodiesDiffuse ground-glass opacitiesIntralobular septal thickeningPulmonary function testsWhole lung lavageGround-glass opacitiesPeriodic acid-Schiff stainMyositis panelParatracheal lymphProductive coughProgressive dyspneaRadiological improvementRespiratory failureAdverse eventsSeptal thickeningHigher detectable levelsRespiratory departmentBronchoalveolar lavageIncreased Levels of Galectin-3 in Critical COVID-19
Nikitopoulou I, Vassiliou A, Athanasiou N, Jahaj E, Akinosoglou K, Dimopoulou I, Orfanos S, Dimakopoulou V, Schinas G, Tzouvelekis A, Aidinis V, Kotanidou A. Increased Levels of Galectin-3 in Critical COVID-19. International Journal Of Molecular Sciences 2023, 24: 15833. PMID: 37958814, PMCID: PMC10650562, DOI: 10.3390/ijms242115833.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsCritical COVID-19ICU mortalityGalectin-3Patient cohortPrognostic accuracyCOVID-19Galectin-3 serum levelsIntensive care unit admissionHospitalized COVID-19 patientsCritical COVID-19 patientsGalectin-3 measurementCare unit admissionGalectin-3 levelsIndependent risk factorMultiple organ injurySevere COVID-19Second patient cohortGreek university hospitalGalectin-3 concentrationsUnit admissionActive diseaseRespiratory failureHospital admissionOrgan injury
2022
A modified blood cell GAP (cGAP) to prognosticate outcomes in IPF
Kreuter M, Lee J, Tzouvelekis A, Oldham J, Molyneaux P, Weycker D, Atwood M, Kirchgässler K, Maher T. A modified blood cell GAP (cGAP) to prognosticate outcomes in IPF. 2022, 1790. DOI: 10.1183/13993003.congress-2022.1790.Peer-Reviewed Original Research
2016
Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells
Yu G, Tzouvelekis A, Wang R, Herazo-Maya J, Srivastava A, Woolard T, Mannam P, Lee P, Bianco A, Kaminski N. Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells. QJM 2016, 109: s9-s9. DOI: 10.1093/qjmed/hcw124.001.Peer-Reviewed Original ResearchSH2 domain-containing phosphatase-SHP-2 is a novel regulator of fibroblast homeostasis in Pulmonary Fibrosis
Tzouvelekis A, Yu G, Herazo-maya J, Xylourgidis N, Herzog E, Bennett A, Kaminski N. SH2 domain-containing phosphatase-SHP-2 is a novel regulator of fibroblast homeostasis in Pulmonary Fibrosis. QJM 2016, 109: s20-s20. DOI: 10.1093/qjmed/hcw121.002.Peer-Reviewed Original ResearchP063 The Distribution and Efficacy of MiR-29 Mimicry as a Therapy for Pulmonary Fibrosis Induced by Bleomycin in Mice
Yu G, Wang R, Ibarra G, Tzouvelekis A, Woolard T, herazo-maya J, Sakamoto K, Li Q, Deluliis G, Ahnangari F, Vukmirovic M, Aurelien N, Adams T, Munivar A, Kaminski N. P063 The Distribution and Efficacy of MiR-29 Mimicry as a Therapy for Pulmonary Fibrosis Induced by Bleomycin in Mice. QJM 2016, 109: s42-s43. DOI: 10.1093/qjmed/hcw124.036.Peer-Reviewed Original ResearchP056 Loss of MAP Kinase Phosphatase 5 (MKP5) attenuates fibrotic responses in-vitro and in-vivo
Tzouvelekis A, Xylourgidis N, Kisuk M, Yu G, Herazo-maya J, Aurelien N, Adams T, Woolard T, Ibarra G, Deiuliis G, Binzenhöfer L, Bennett A, Kaminski N. P056 Loss of MAP Kinase Phosphatase 5 (MKP5) attenuates fibrotic responses in-vitro and in-vivo. QJM 2016, 109: s40-s40. DOI: 10.1093/qjmed/hcw124.028.Peer-Reviewed Original Research